|
| 37606673 | Evaluation of Large-Scale Proteomics for Prediction of Cardiovascular Events. | JAMA | 2023 |
| 32785614 | Efficacy and Safety of PCSK9 Inhibition With Evolocumab in Reducing Cardiovascular Events in Patients With Metabolic Syndrome Receiving Statin Therapy: Secondary Analysis From the FOURIER Randomized Clinical Trial. | JAMA Cardiol | 2021 |
| 33826209 | The effect of the cardiac myosin activator, omecamtiv mecarbil, on right ventricular structure and function in chronic systolic heart failure (COSMIC-HF). | Eur J Heart Fail | 2021 |
| 33185990 | Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure. | N Engl J Med | 2021 |
| 32805181 | Real-World Analysis of Guideline-Based Therapy After Hospitalization for Heart Failure. | Journal of the American Heart Association | 2020 |
| 32432684 | Efficacy of Evolocumab on Cardiovascular Outcomes in Patients With Recent Myocardial Infarction: A Prespecified Secondary Analysis From the FOURIER Trial. | JAMA Cardiol | 2020 |
| 32312223 | Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis. | Stroke | 2020 |
| 32347885 | Effect of Evolocumab on Type and Size of Subsequent Myocardial Infarction: A Prespecified Analysis of the FOURIER Randomized Clinical Trial. | JAMA Cardiol | 2020 |
| 31863532 | Association between systolic ejection time and outcomes in heart failure by ejection fraction. | Eur J Heart Fail | 2020 |
| 31116355 | Effect of the PCSK9 Inhibitor Evolocumab on Total Cardiovascular Events in Patients With Cardiovascular Disease: A Prespecified Analysis From the FOURIER Trial. | JAMA Cardiol | 2019 |
| 29530884 | Inflammatory and Cholesterol Risk in the FOURIER Trial. | Circulation | 2018 |
| 30071950 | Heart Failure With Preserved Ejection Fraction Expert Panel Report: Current Controversies and Implications for Clinical Trials. | JACC Heart Fail | 2018 |
| 29626068 | Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER. | Circulation | 2018 |
| 28304224 | Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. | N Engl J Med | 2017 |
| 28345190 | New medicinal products for chronic heart failure: advances in clinical trial design and efficacy assessment. | Eur J Heart Fail | 2017 |
| 28813214 | Cognitive Function in a Randomized Trial of Evolocumab. | N Engl J Med | 2017 |
| 28927706 | Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. | Lancet Diabetes Endocrinol | 2017 |
| 28207168 | Design and rationale of the EBBINGHAUS trial: A phase 3, double-blind, placebo-controlled, multicenter study to assess the effect of evolocumab on cognitive function in patients with clinically evident cardiovascular disease and receiving statin background lipid-lowering therapy-A cognitive study of patients enrolled in the FOURIER trial. | Clin Cardiol | 2017 |
| 28215937 | Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. | Lancet Diabetes and Endocrinology,The | 2017 |
| 27914656 | Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. | Lancet | 2016 |
| 27102113 | PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role. | J Lipid Res | 2016 |
| 26920601 | Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial. | Am Heart J | 2016 |
| 27324688 | Erratum to "Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency" [Eur J Heart Fail 2016;18:482-489]. | European Journal of Heart Failure | 2016 |
| 27071916 | Traditional and new composite endpoints in heart failure clinical trials: facilitating comprehensive efficacy assessments and improving trial efficiency. | European Journal of Heart Failure | 2016 |
| 26547291 | A Phase 3 Study of Evolocumab (AMG 145) in Statin-Treated Japanese Patients at High Cardiovascular Risk. | American Journal of Cardiology | 2016 |
| 25282520 | Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. | Lancet, The | 2015 |
| 24662398 | Effects of evolocumab (AMG 145), a monoclonal antibody to PCSK9, in hypercholesterolemic, statin-treated Japanese patients at high cardiovascular risk--primary results from the phase 2 YUKAWA study. | Circulation Journal | 2014 |
| 24390425 | F-box protein FBXL16 binds PP2A-B55α and regulates differentiation of embryonic stem cells along the FLK1+ lineage. | Molecular and Cellular Proteomics | 2014 |
| 24014831 | Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia. | Circulation | 2013 |
| 15649468 | Loss of Apaf-1 leads to partial rescue of the HAND2-null phenotype. | Dev Biol | 2005 |
| 11566499 | Embryonic neuronal death due to neurotrophin and neurotransmitter deprivation occurs independent of Apaf-1. | Neuroscience | 2001 |
| 11504943 | Apaf-1 deficiency and neural tube closure defects are found in fog mice. | Proceedings of the National Academy of Sciences of the United States of America | 2001 |
| 10845059 | Apoptosis in neural development and disease. | Annual Review of Neuroscience | 2000 |
| 10656767 | Adult Apaf-1-deficient mice exhibit male infertility. | Developmental Biology | 2000 |